Dr. Mark Kris on Immunotherapy and Frontline Options for Patients With NSCLC
In Partnership With:
Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, explains what community oncologists need to know regarding immunotherapy and frontline treatment options for patients with non–small cell lung cancer (NSCLC).
Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, explains what community oncologists need to know regarding immunotherapy and frontline treatment options for patients with non—small cell lung cancer (NSCLC).
During the Cleveland Clinic/OncLive 2016 State of the Science Summit on Lung Cancer, Kris explains how the quantity of therapies available for patients have significantly increased over the past decade. The landscape has evolved, he adds, with the development of immunotherapy and targeted therapies.
Going forward, community oncologists need to determine how to best choose amongst the available therapies for their individual patients. They can do this by utilizing the resources they may have at their disposal, Kris says.
